|
T67776 |
PCSK9-IN-11
|
|
Others
|
|
PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity. PCSK9-IN-11 shows inhibitory activity of PCSK9 transcription in HepG2 cells (IC50= 5.7 μM). PCSK9-IN-11 can increase LDL receptor (LDLR) protein l... |
|
T72025 |
PCSK9-IN-10
|
|
Serine/threonin kinase
|
|
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Li... |
|
T39528 |
PCSK9-IN-2
|
PCSK9-IN-2 |
|
|
PCSK9-IN-2 is a newly developed small molecule that effectively inhibits the protein-protein interaction (PPI) between PCSK9 and LDLR. It has been found to have a potent inhibitory activity with an IC50 value of 7.57 μM. |
|
T64362 |
AZD0780
|
PCSK9-IN-12,EX-A6975 |
Others
|
|
AZD0780 (EX-A6975) exhibits bind affinity for PCSK9 ( Kd ＜200 nM). AZD0780 has research value in cholesterol metabolism. |
|
T39685 |
PCSK9 degrader 1
|
|
|
|
PCSK9 degrader 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) degrader. PCSK9 degrader 1 does not affect PCSK9 function. |
|
T13813 |
PCSK9 ligand 1
|
|
Others
|
|
PCSK9 ligand 1 is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9(Ki of 107 nM). |
|
T75147 |
PCSK9-IN-18
|
|
|
|
PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor with a K D value of <200 nM [1] . |
|
T73008 |
PCSK9-IN-13
|
|
|
|
PCSK9-IN-13 is a potent inhibitor of PCSK9, effectively preventing the binding of PCSK9 to low-density lipoprotein (LDL) receptors through its mechanism of action. It exhibits this inhibitory activity with an IC 50 value... |
|
T81535 |
PCSK9-IN-20
|
|
|
|
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor exhibiting an IC50 value of 3.96 µM, shown to reduce PCSK9 and enhance LDLR protein levels in vitro [1]. |
|
T74167 |
PCSK9-IN-3
|
|
|
|
PCSK9-IN-3 is a next-generation tricyclic peptide inhibitor of PCSK9, characterized by its novel structure, high potency, and oral bioavailability. |
|
T60764 |
PCSK9 modulator-4
|
|
|
|
PCSK9 modulator-4 (Compound 21) can be used in hyperlipidemia research that is a potent PCSK9 modulator (EC 50 = 0.15 nM). PCSK9 is a lowering low-density lipoprotein cholesterol (LDL-C) target that is recently validated... |
|
T60646 |
PCSK9 modulator-3
|
|
|
|
PCSK9 modulator-3 (Compound 13) is a potent PCSK9 modulator with an EC 50 value of 2.46 nM that has the potential in the hyperlipidemia research. PCSK9 is a recently proved target for lowering low-density lipoprotein cho... |
|
T79051 |
PCSK9-IN-15
|
|
|
|
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K D <200 nM) that plays a crucial role in cholesterol metabolism by regulating blood levels of low-density lipoprotein ch... |
|
T79030 |
PCSK9-IN-14
|
|
|
|
PCSK9-IN-14, also known as compound Ia-8, is a potent inhibitor of PCSK9 [1]. |
|
T79053 |
PCSK9-IN-17
|
|
|
|
PCSK9-IN-17 is a PCSK9 inhibitor utilized in the research of cholesterol metabolism. |
|
T60541 |
PCSK9 modulator-2
|
|
|
|
PCSK9 modulator-2 (Compound 1) is a potent PCSK9 modulator (EC 50 = 202 nM) that has the potential to be used in hyperlipidemia research. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently validated ther... |
|
T79239 |
PCSK9-IN-19
|
|
|
|
PCSK9-IN-19 (Compound 1), a PCSK9 inhibitor, is utilized in researching the treatment of high LDL-cholesterol levels and the prevention of coronary artery disease [1]. |
|
T79052 |
PCSK9-IN-16
|
|
|
|
PCSK9-IN-16, holds potential for research into hypercholesterolemia and other cardiovascular diseases [1]. |
|
T9920 |
Evolocumab
|
|
Others
|
|
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). |
|
T70068 |
AT-1015 hydrochloride monohydrate
|
|
|
|
AT-1015 hydrochloride monohydrate is a serotonin (5-HT)2 receptor antagonist that blocks vascular and platelet 5-HT2A receptors. |
|
T4058 |
R-IMPP
|
|
Others
,
Serine/threonin kinase
|
|
R-IMPP is an inhibitor of PCSK9 translation. R-IMPP stimulates uptake of LDL-C in hepatoma cells by increasing LDL-R levels, without altering levels of secreted transferrin. |
|
TP1881L1 |
Pep 2-8 ammonium salt(1541011-97-5 free base)
|
|
Others
|
|
Pep 2-8 ammonium salt is Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Potent inhibitor of PCSK9 binding to LDL receptor (IC50 = 0.8 μM). Restores LDL uptake in HepG2 cells treated with PCSK9. |
|
T8645 |
PF-06446846
|
|
Others
|
|
PF 06446846 is a potent and selective PCSK9 inhibitor |
|
T9276 |
SBC-115337
|
|
Others
,
Serine/threonin kinase
|
|
SBC-115337 is a PCSK9 inhibitor. |
|
T2626 |
SBC-115076
|
SBC115076 |
Others
,
Serine/threonin kinase
|
|
SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist. |
|
T76739 |
Bococizumab
|
RN316,PF-04950615 |
Others
|
|
Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to... |
|
T16491 |
PF-06446846 hydrochloride
|
|
Others
|
|
PF-06446846 hydrochloride, an orally active and highly selective inhibitor, targets Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) translation by inducing ribosomal stalling at approximately codon 34, effectively ... |
|
T4524 |
SBC-110736
|
SBC110736 |
Others
,
Serine/threonin kinase
|
|
SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor |
|
T9916 |
Alirocumab
|
|
Others
|
|
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. |
|
TP1881 |
Pep2-8
|
Pep 2-8 |
|
|
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Potent inhibitor of PCSK9 binding to LDL receptor (IC50 = 0.8 μM). Restores LDL uptake in HepG2 cells treated with PCSK9. |
|
T77014 |
Frovocimab
|
|
|
|
Frovocimab (LY 3015014), a humanized IgG4 monoclonal antibody (mAb), acts by neutralizing PCSK9. This mechanism effectively prevents PCSK9 from binding to the LDL receptor (LDLR) while allowing for the normal proteolytic... |
|
T78718 |
Dim16
|
|
|
|
Dim16, a dual inhibitor of PCSK9/HMG-CoAR, demonstrates potent activity with an IC50 of 19 nM against PCSK9 and significantly impedes PCSK9-LDLR interaction with an IC50 of 0.8 nM, leading to an enhanced LDL uptake in He... |
|
T74730 |
SPC4061
|
|
|
|
SPC4061, a potent PCSK9 inhibitor and an antisense nucleotide, specifically targets the lock-in nucleic acid (LNA) of PCSK9. This action is relevant for researching hypercholesterolemia and associated diseases [1] [2]. |
|
T74573 |
Bezeparsen
|
|
|
|
Bezeparsen is a PCSK9 synthesis inhibitor [1] . |
|
T72221 |
PF-06815345 hydrochloride
|
|
|
|
PF-06815345 hydrochloride, an orally active potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), has an IC50 value of 13.4 μM. It significantly decreases in vivo PCSK9 levels in mice. |
|
T78013 |
Pep2-8 TFA
|
|
|
|
Pep2-8 is a peptide that has demonstrated enhanced antagonistic activity against proprotein convertase subtilin/kexin type 9 (PCSK9) [1]. |
|
T77140 |
Ralpancizumab
|
|
|
|
Ralpancizumab, a selective PCSK9 inhibitor, shows potential for use in hemorrhagic stroke [1]. |
|
T70069 |
MDK6465
|
|
|
|
MDK6465, also known as PCSK9-IN-8b, is a novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). MDK6465 has CAS#1900686-46-5. the last 4 digits are used in its na... |
|
T77144 |
Recaticimab
|
|
|
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance the degradation of this enzyme. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte... |
|
T80608 |
Ebronucimab
|
AK102 |
|
|
Ebronucimab (AK102), an IgG1-λ2 antibody, specifically targets PCSK9 and is predominantly produced in CHO DG44 (Chinese Hamster Ovary) cells [1]. |
|
T77113 |
Ongericimab
|
|
|
|
Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9 with demonstrated lipid-lowering efficacy. It is utilized in the research of hypercholesterolemia and hyperlipidemia [1]. |
|
T77058 |
Lerodalcibep
|
|
|
|
Lerodalcibep (LIB003), a lipid-lowering agent, consists of a PCSK9-binding domain (adnectin) fused with human serum albumin, forming a recombinant fusion protein. It is utilized in the research of hypercholesterolemia an... |
|
T16322 |
Nicodicosapent
|
|
Others
|
|
Nicodicosapent is a fatty acid niacin conjugate. It is also an inhibitor of the sterol regulatory element-binding protein (SREBP). The sterol regulatory element-binding protein (SREBP) is a key regulator of cholesterol m... |
